Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia; Augusto Villegas; Davey B. Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki Hyeong Lee; Maike de Wit; Byoung Chul Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young‐Chul Kim; Christos S. Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E. Gray; Luis Paz‐Ares; Javier de Castro; Corinne Faivre‐Finn; Martin Reck; Johan Vansteenkiste; David R. Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A. Dennis; Mustafa Özgüroğlu

doi:10.1056/nejmoa1809697

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Durvalumab therapy resulted in significantly longer overall survival than placebo. No new safety signals were identified. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Antonia et al. (2018) studied this question.

synapsesocial.com/papers/69d81c52b5518339b2ae2e8d https://doi.org/10.1056/nejmoa1809697

View Full Paper

Ask AI

Bookmark

Share

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Ask about this paper

Abstract

Discussion

Cite This Study

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading